Page 31 of 111
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version

11-06/07 :: June/July 2011

nanotimes

Companies Facts

the year-ago period. License and research revenues were $2.5 million versus $3.3 million in the second quarter of 2010. Product sales and services in the current quarter increased to $2.3 million versus $1.9 million in the second quarter of 2010. Other reve- nues during the current quarter, including royalties on the sale of Coreg CR™, were $2.0 million versus $2.4 million in the year-ago period.

from sunlight, enabling the production of superior Selective Emitter solar cells. According to industry es- timates, Selective Emitter technology could represent 13 percent of crystalline silicon solar cell production by 2013 and up to 38 percent by 2020.

Image: Silicon inks from DuPont Innovalight boost the amount of electricity produced from sunlight, enabling the production of superior Selective Emitter solar cells. © Dupont/Innovalight

http://www.dupont.com D F

yesol Ltd. announced the issuance of 2,076,843 ordinary fully paid shares at AUD 0.3852 per

share. The shares have been issued upon conversion of a convertible security.

http://ww.dyesol.com

lamel Technologies S.A. (NASDAQ: FLML) reported total revenues in the second quarter 2011 of $6.8 million, compared to $7.5 million in

Furthermore, Flamel Technologies SA and Digna Biotech SL announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products. The agreement has been structured to leverage Digna’s groundbreaking research, preclinical and clinical development efforts, and Flamel’s for- mulation expertise in creating safer, more efficacious products using its innovative proprietary drug delive- ry platforms, Medusa®

and Micropump® .

Flamel will be primarily responsible for the formu- lation and manufacturing process development and

Costs and expenses during the second quarter of 2011 were $(10.4) million versus $(12.2) million in the year-ago period. Costs of goods and services sold in the quarter totaled $(1.9) million versus $(1.6) million in the second quarter of 2010. Research and development expenses were $(5.9) million versus $(7.9) million in the second quarter of 2010. SG&A declined to $(2.5) million from $(2.8) million in the year-ago period. Net loss in the second quarter of 2011 was $(3.5) million, compared to a net loss of $(4.3) million in the second quarter of 2010. Net loss per share (basic) for the second quarter of 2011 was ($0.14), compared to a net loss per share (basic) in the year-ago period of ($0.18).

31

Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97  |  98  |  99  |  100  |  101  |  102  |  103  |  104  |  105  |  106  |  107  |  108  |  109  |  110  |  111